NO20076663L - Immunoglobuliner - Google Patents
ImmunoglobulinerInfo
- Publication number
- NO20076663L NO20076663L NO20076663A NO20076663A NO20076663L NO 20076663 L NO20076663 L NO 20076663L NO 20076663 A NO20076663 A NO 20076663A NO 20076663 A NO20076663 A NO 20076663A NO 20076663 L NO20076663 L NO 20076663L
- Authority
- NO
- Norway
- Prior art keywords
- immunoglobulins
- antibodies
- disorders
- prevention
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0513766A GB0513766D0 (en) | 2005-07-05 | 2005-07-05 | Immunoglobulins |
GB0525448A GB0525448D0 (en) | 2005-12-14 | 2005-12-14 | Immunoglobulins |
PCT/EP2006/006535 WO2007003421A2 (en) | 2005-07-05 | 2006-07-03 | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20076663L true NO20076663L (no) | 2008-02-27 |
Family
ID=37604821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076663A NO20076663L (no) | 2005-07-05 | 2007-12-28 | Immunoglobuliner |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1899377B1 (es) |
JP (1) | JP2009500363A (es) |
KR (1) | KR20080030960A (es) |
AU (1) | AU2006265276B2 (es) |
BR (1) | BRPI0612734A2 (es) |
CA (1) | CA2614076A1 (es) |
CR (1) | CR9623A (es) |
CY (1) | CY1113310T1 (es) |
DK (1) | DK1899377T3 (es) |
EA (1) | EA014291B1 (es) |
ES (1) | ES2391902T3 (es) |
HK (1) | HK1115598A1 (es) |
HR (1) | HRP20120851T1 (es) |
IL (1) | IL188282A (es) |
MA (1) | MA29625B1 (es) |
NO (1) | NO20076663L (es) |
NZ (1) | NZ564567A (es) |
PL (1) | PL1899377T3 (es) |
PT (1) | PT1899377E (es) |
SG (1) | SG162829A1 (es) |
SI (1) | SI1899377T1 (es) |
WO (1) | WO2007003421A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
SI2158315T1 (sl) | 2007-06-25 | 2016-05-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi |
NZ584911A (en) * | 2007-11-02 | 2011-08-26 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use thereof |
WO2010004031A2 (en) * | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
PT3723858T (pt) | 2018-12-21 | 2022-02-02 | Kymab Ltd | Anticorpo biespecífico fixaxfx com cadeia leve comum |
GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
PT1711530E (pt) * | 2003-12-22 | 2009-10-22 | Glaxo Group Ltd | Imunoglobulinas neutralizantes de nogo-a para o tratamento de doenças neurológicas |
-
2006
- 2006-07-03 KR KR1020077031031A patent/KR20080030960A/ko not_active Application Discontinuation
- 2006-07-03 CA CA002614076A patent/CA2614076A1/en not_active Abandoned
- 2006-07-03 WO PCT/EP2006/006535 patent/WO2007003421A2/en active Application Filing
- 2006-07-03 SI SI200631454T patent/SI1899377T1/sl unknown
- 2006-07-03 AU AU2006265276A patent/AU2006265276B2/en not_active Ceased
- 2006-07-03 NZ NZ564567A patent/NZ564567A/en not_active IP Right Cessation
- 2006-07-03 PL PL06776123T patent/PL1899377T3/pl unknown
- 2006-07-03 PT PT06776123T patent/PT1899377E/pt unknown
- 2006-07-03 JP JP2008519855A patent/JP2009500363A/ja not_active Ceased
- 2006-07-03 ES ES06776123T patent/ES2391902T3/es active Active
- 2006-07-03 DK DK06776123.9T patent/DK1899377T3/da active
- 2006-07-03 SG SG201004551-6A patent/SG162829A1/en unknown
- 2006-07-03 BR BRPI0612734-7A patent/BRPI0612734A2/pt not_active IP Right Cessation
- 2006-07-03 EP EP06776123A patent/EP1899377B1/en active Active
- 2006-07-03 EA EA200702634A patent/EA014291B1/ru not_active IP Right Cessation
-
2007
- 2007-12-20 IL IL188282A patent/IL188282A/en not_active IP Right Cessation
- 2007-12-20 CR CR9623A patent/CR9623A/es not_active Application Discontinuation
- 2007-12-28 NO NO20076663A patent/NO20076663L/no not_active Application Discontinuation
-
2008
- 2008-01-09 MA MA30565A patent/MA29625B1/fr unknown
- 2008-05-15 HK HK08105409.6A patent/HK1115598A1/xx not_active IP Right Cessation
-
2012
- 2012-10-23 HR HRP20120851TT patent/HRP20120851T1/hr unknown
- 2012-11-05 CY CY20121101051T patent/CY1113310T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1899377T1 (sl) | 2012-12-31 |
MA29625B1 (fr) | 2008-07-01 |
CA2614076A1 (en) | 2007-01-11 |
NZ564567A (en) | 2010-09-30 |
ES2391902T3 (es) | 2012-11-30 |
PT1899377E (pt) | 2012-11-20 |
HK1115598A1 (en) | 2008-12-05 |
WO2007003421A2 (en) | 2007-01-11 |
AU2006265276A1 (en) | 2007-01-11 |
IL188282A0 (en) | 2008-04-13 |
EP1899377B1 (en) | 2012-08-22 |
SG162829A1 (en) | 2010-07-29 |
BRPI0612734A2 (pt) | 2010-11-30 |
HRP20120851T1 (hr) | 2012-11-30 |
JP2009500363A (ja) | 2009-01-08 |
PL1899377T3 (pl) | 2013-01-31 |
CR9623A (es) | 2008-04-10 |
KR20080030960A (ko) | 2008-04-07 |
DK1899377T3 (da) | 2012-11-12 |
EP1899377A2 (en) | 2008-03-19 |
EA200702634A1 (ru) | 2008-06-30 |
WO2007003421A3 (en) | 2007-04-12 |
IL188282A (en) | 2011-04-28 |
AU2006265276B2 (en) | 2011-10-13 |
CY1113310T1 (el) | 2016-04-13 |
EA014291B1 (ru) | 2010-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062767L (no) | Immunoglobuliner | |
NO20082699L (no) | Immunoglobuliner | |
WO2008079246A3 (en) | Cd44 antibodies | |
NO20076663L (no) | Immunoglobuliner | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
TW200709817A (en) | Platform antibody compositions | |
MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2007064883A3 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2006058868A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
WO2006025991A3 (en) | Isoindoline compounds and methods of making and using the same | |
EA201000424A1 (ru) | Антитела к il-23 | |
NO20055894L (no) | Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer | |
EA200901263A1 (ru) | Конденсированный аминопиридин в качестве ингибиторов hsp90 | |
WO2007068894A3 (en) | Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease | |
WO2004041203A3 (en) | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | |
NO20045323L (no) | Antistoffer | |
WO2006096489A3 (en) | Anti-m-csf antibody compositions having reduced levels of endotoxin | |
WO2006058869A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
WO2006058867A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
WO2007050793A3 (en) | Methods and compositions for the treatment of marfan syndrome and associated disorders | |
WO2009071689A3 (de) | 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen | |
WO2007059341A3 (en) | Pyrazolothiazole protein kinase modulators | |
WO2007017146A3 (en) | Use of collismycin and derivatives thereof as oxidative stress inhibitors | |
DK1441723T3 (da) | Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension | |
WO2004073625A3 (en) | Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXO GROUP LTD, GB |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |